BACKGROUND: Painful physical symptoms (PPS) are both common and reduce the likelihood of remission in major depressive disorder (MDD), based upon results of clinical trials in selected populations. Whether PPS significantly contribute to poorer treatment outcome overall in primary or specialty psychiatric care settings remains unclear. METHOD: Out-patients (n=2876) with MDD were treated in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial with citalopram up to 60 mg/day for up to 14 weeks. Presence of painful symptoms, as well as severity of depression, physical illness, and demographic and treatment factors were examined. Time to and overall rates of remission were analysed in relation to the presence of PPS. RESULTS: Of the participants, 80% complained of PPS. These patients, both in primary and specialty psychiatric settings, had significantly lower remission rates and took longer to remit. Increasing severity of PPS was associated with greater physical illness burden, lower socio-economic status, absence of private insurance and being female, African-American or Hispanic. After adjustment for these factors, patients with PPS no longer had significantly poorer treatment outcomes. CONCLUSIONS: Presence and severity of PPS is an indicator of MDD that may have poorer treatment outcome with an initial selective serotonin reuptake inhibitor. These poorer treatment outcomes are multifactorial, however, and are not explained by the presence and severity of pain per se.
BACKGROUND: Painful physical symptoms (PPS) are both common and reduce the likelihood of remission in major depressive disorder (MDD), based upon results of clinical trials in selected populations. Whether PPS significantly contribute to poorer treatment outcome overall in primary or specialty psychiatric care settings remains unclear. METHOD: Out-patients (n=2876) with MDD were treated in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial with citalopram up to 60 mg/day for up to 14 weeks. Presence of painful symptoms, as well as severity of depression, physical illness, and demographic and treatment factors were examined. Time to and overall rates of remission were analysed in relation to the presence of PPS. RESULTS: Of the participants, 80% complained of PPS. These patients, both in primary and specialty psychiatric settings, had significantly lower remission rates and took longer to remit. Increasing severity of PPS was associated with greater physical illness burden, lower socio-economic status, absence of private insurance and being female, African-American or Hispanic. After adjustment for these factors, patients with PPS no longer had significantly poorer treatment outcomes. CONCLUSIONS: Presence and severity of PPS is an indicator of MDD that may have poorer treatment outcome with an initial selective serotonin reuptake inhibitor. These poorer treatment outcomes are multifactorial, however, and are not explained by the presence and severity of pain per se.
Authors: Jennifer L Warner-Schmidt; Kimberly E Vanover; Emily Y Chen; John J Marshall; Paul Greengard Journal: Proc Natl Acad Sci U S A Date: 2011-04-25 Impact factor: 11.205
Authors: Kenneth E Freedland; Robert M Carney; Junichiro Hayano; Brian C Steinmeyer; Rebecca L Reese; Annelieke M Roest Journal: J Psychosom Res Date: 2012-01-28 Impact factor: 3.006
Authors: Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-11 Impact factor: 5.270
Authors: Susan G Ball; Durisala Desaiah; Melissa E Spann; Qi Zhang; James M Russell; Michael J Robinson; Koen Demyttenaere Journal: Prim Care Companion CNS Disord Date: 2011
Authors: Waguih William IsHak; Alexander J Steiner; Anna Klimowicz; Kaitlyn Kauzor; Jonathan Dang; Brigitte Vanle; Christina Elzahaby; Mark Reid; Lekeisha Sumner; Itai Danovitch Journal: Psychopharmacol Bull Date: 2018-01-15
Authors: Ellen L Poleshuck; Stephanie A Gamble; Kelly Bellenger; Naiji Lu; Xin Tu; Silvia Sörensen; Donna E Giles; Nancy L Talbot Journal: J Psychosom Res Date: 2014-07-26 Impact factor: 3.006